Samsung Bioepis answers biologics question with resounding 'yes'

22 August 2017

There is little doubt that, since it started life in the drug development industry just five years ago, Samsung Bioepis has passed its first test with flying colors.

That test was to become a major player in the development of biosimilar medicines, the area through which the company chose to enter the industry in February 2012.

At that time, Samsung Bioepis, which is a joint collaboration between Korean conglomerate Samsung and US biotech Biogen (Nasdaq: BIIB), quickly realized the value that biosimilars could bring to patients over the coming decades by bringing increased access to high-quality medicines, says company spokesman Mingi Hyun.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK